A meta-analysis was published on the safety of Tirzepatide by Zeng Q et al., in October 2023, whereby, Tirzepatide was not found to be significantly associated with an increased risk of pancreatitis when compared to all control groups consisting of basal insulin (glargine or degludec), selective GLP1-RA (dulaglutide or semaglutide once weekly), and placebo (RR 1.46, [95% CI] 0.59 to 3.61; I2 = 0.0%, p = 0.436). Here, INS is linked to pancreatitis.